MOLIVO-1/AMLSG33-22: To investigate PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated re-lapsed/refractory AML or MDS/AML patients (clinicaltrialsregister.eu) - Oct 1, 2026 - P1/2 | N=27 | Active, not recruiting | Sponsor: Medizinische Hochschule Hannover | Suspended ➔ Active, not recruiting
Enrollment closed • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • IDH1
|